Turkish Validation of the Parkinson Disease Cognitive Functional Rating Scale

NCT07253376 | Enrolling By Invitation DMC

• 1 other identifier: TABED 1-25-1618
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 2

Brief Summary

The aim of the present study is to translate the Parkinson's Disease-Cognitive Functional Rating Scale into Turkish (PD-CFRS-Turkish version) and to evaluate its validity and reliability.

Conditions

Parkinson's Disease; Cognitive Functions; Cognitive Functioning; Cognition; Reliability and Validity

Keywords

Parkinson's disease; Cognition; Cognitive Functions; Reliability; Validity

Outcome Measures

Primary Outcomes (1)

• Validity of the Turkish Version of the Parkinson's Disease Cognitive Functional Rating Scale

  Parkinson's Disease Cognitive Functional Rating Scale assesses the functional impact of cognitive impairment in individuals with Parkinson's disease. The 12-item scale assesses cognitive impairment while minimizing motor effects. Items are scored 0-2. Unperformed tasks (score 8) are replaced by the average of scored items and summed. The total score ranges from 0 to 24. Higher scores indicate worse outcomes. The validity of the Turkish version of the scale will be evaluated through convergent and discriminant construct analyses. Convergent validity will be assessed by examining partial Pearson correlations between Parkinson's Disease Cognitive Functional Rating Scale scores and Mini-Mental State Examination and Montreal Cognitive Assessment scores. Discriminant validity will be analyzed using binary logistic regression with Mini-Mental State Examination and Montreal Cognitive Assessment scores and disease duration as independent variables.

  Baseline

Secondary Outcomes (6)

• Reliability of the Turkish Version of the Parkinson's Disease Cognitive Functional Rating Scale

  Repeated measurements will be conducted at a 2 week interval.

• Mini Mental State Examination Score

  Baseline

• Montreal Cognitive Assessment Score

  Baseline

• MDS-Unified Parkinson's Disease Rating Scale Part 3: Motor Examination Score

  Baseline

• Hoehn and Yahr Scale

  Baseline

Study Arms (1)

Individuals with Parkinson's Disease

Participants diagnosed with Parkinson's disease who will complete the Turkish version of the Parkinson's Disease-Cognitive Functional Rating Scale (PD-CFRS) for validity and reliability analysis.

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study has a multicenter design. The participating sites are as follows: Ankara Bilkent City Hospital, Physical Therapy and Rehabilitation Hospital- designated as Site 1. Participants at this site will include individuals diagnosed with Parkinson's disease (PD) who are currently receiving treatment at the hospital and have consented to participate in the study. Gazi University, Faculty of Health Sciences, Neurological Physical Therapy and Rehabilitation Unit - designated as Site 2. Participants at this site will include individuals diagnosed with PD who have been referred to the unit and have consented to participate in the study.

You may qualify if:

• Clinically diagnosed with idiopathic Parkinson's disease by a neurologist.
• Evaluated between Stage 1-3 according to the Hoehn and Yahr Staging Scale.
• Aged 40 years or older.
• Agreed to participate in the study after being given sufficient information.

You may not qualify if:

• Patients with a Montreal Cognitive Assessment score of 20 and below.
• Patients with cardiovascular, vestibular, musculoskeletal or additional neurological disease.

Sponsors & Collaborators

• Gazi University: lead
• T.C. Sağlık Bakanlığı Ankara Bilkent Şehir Hastanesi: collaborator

Study Sites (2)

Gazi University, Faculty of Health Sciences

Ankara, 06490, Turkey (Türkiye)

Location

Ankara Bilkent City Hospital, Physical Medicine and Rehabilitation Hospital

Ankara, 06800, Turkey (Türkiye)

Location

Related Publications (13)

• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. doi: 10.1111/j.1600-0447.1983.tb09716.x.

  PMID: 6880820 BACKGROUND

• Snaith RP. The Hospital Anxiety And Depression Scale. Health Qual Life Outcomes. 2003 Aug 1;1:29. doi: 10.1186/1477-7525-1-29.

  PMID: 12914662 BACKGROUND

• Ozdilek B, Kenangil G. Validation of the Turkish Version of the Montreal Cognitive Assessment Scale (MoCA-TR) in patients with Parkinson's disease. Clin Neuropsychol. 2014;28(2):333-43. doi: 10.1080/13854046.2014.881554. Epub 2014 Feb 17.

  PMID: 24528299 BACKGROUND

• Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x.

  PMID: 15817019 BACKGROUND

• Kulisevsky J, Fernandez de Bobadilla R, Pagonabarraga J, Martinez-Horta S, Campolongo A, Garcia-Sanchez C, Pascual-Sedano B, Ribosa-Nogue R, Villa-Bonomo C. Measuring functional impact of cognitive impairment: validation of the Parkinson's disease cognitive functional rating scale. Parkinsonism Relat Disord. 2013 Sep;19(9):812-7. doi: 10.1016/j.parkreldis.2013.05.007. Epub 2013 Jun 15.

  PMID: 23773412 BACKGROUND

• Kline, P. (1994). An Easy Guide to Factor Analysis (1st ed.). Routledge.

  BACKGROUND

• Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427-42. doi: 10.1212/wnl.17.5.427. No abstract available.

  PMID: 6067254 BACKGROUND

• Aydemir Ö,Kirpinar İ,Sati T,Uykur B,Cengisiz C

  BACKGROUND

• Gungen C, Ertan T, Eker E, Yasar R, Engin F. [Reliability and validity of the standardized Mini Mental State Examination in the diagnosis of mild dementia in Turkish population]. Turk Psikiyatri Derg. 2002 Winter;13(4):273-81. Turkish.

  PMID: 12794644 BACKGROUND

• Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol. 1993 Dec;46(12):1417-32. doi: 10.1016/0895-4356(93)90142-n.

  PMID: 8263569 BACKGROUND

• Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N; Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15;23(15):2129-70. doi: 10.1002/mds.22340.

  PMID: 19025984 BACKGROUND

• Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98. doi: 10.1016/0022-3956(75)90026-6. No abstract available.

  PMID: 1202204 BACKGROUND

• Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002 Feb;52(2):69-77. doi: 10.1016/s0022-3999(01)00296-3.

  PMID: 11832252 BACKGROUND

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Study Officials

• Emre Adıgüzel, Prof., MD.

  Ankara City Hospital Bilkent

  STUDY DIRECTOR

• Arzu Güçlü Gündüz, Prof., PT.

  Gazi University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Target Duration: 2 Weeks
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor, PhD, PT

Study Record Dates

• First Submitted: November 19, 2025
• First Posted: November 28, 2025
• Study Start: October 10, 2025
• Primary Completion (Estimated): October 10, 2026
• Study Completion (Estimated): December 10, 2026
• Last Updated: March 19, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

TU (2)